Avadel Pharmaceuticals plc (AVDL)

Market Cap	746.80M
Revenue (ttm)	138.16M
Net Income (ttm)	-72.58M
Shares Out	96.36M
EPS (ttm)	-0.78
PE Ratio	n/a
Forward PE	163.53
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,122,217
Open	8.05
Previous Close	8.00
Day's Range	7.75 - 8.06
52-Week Range	7.39 - 19.09
Beta	1.63
Analysts	Strong Buy
Price Target	20.00 (+158.07%)
Earnings Date	Mar 3, 2025

About AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 7, 1996
• Employees: 154
• Stock Exchange: NASDAQ
• Ticker Symbol: AVDL
• Website: https://www.avadel.com

Analyst Forecast

According to 6 analysts, the average rating for AVDL stock is "Strong Buy." The 12-month stock price forecast is $20.0, which is an increase of 158.07% from the latest price.

Price Target

$20.0

(158.07% upside)

Analyst Consensus: Strong Buy